INTRODUCTION
This podcast series activity explores the latest advances transforming the diagnosis and management of fibrotic interstitial lung diseases (ILDs).
Launch/Release Date: October 29, 2026
Activity Expiration Date: September 30, 2027
TARGET AUDIENCE
This activity is designed for healthcare providers who are involved in the diagnosis and clinical care of patients with IPF. This may include physicians, physician associates, nurse practitioners, registered nurses, and pharmacists.
LEARNING OBJECTIVES
Upon completion of this enduring material, participants should be able to:
- Recognize the heterogeneity, disease burden, and racial and ethnic disparities across interstitial lung disease (ILD) populations to support more equitable, timely, and risk-informed care.
- Differentiate idiopathic pulmonary fibrosis (IPF) and related ILDs from other causes of chronic respiratory symptoms by integrating clinical features, high-resolution imaging, and multidisciplinary diagnostic frameworks.
- Apply personalized, evidence-based strategies to optimize therapy, manage tolerability, and support long-term treatment persistence in IPF and progressive fibrosing ILD, including emerging oral, inhaled, and combination therapies.
- Integrate multidisciplinary care pathways, practical diagnostic algorithms, and patient-centered communication strategies to improve coordination, shared decision-making, and longitudinal ILD management.
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Review all modules associated with this course.
- Successfully complete the post-test (80% accuracy).
- Complete the CME/CE evaluation.
- The estimated time to complete this activity is 1.50 hours.
ACCREDITATION STATEMENTS
In support of improving patient care, this activity has been planned and implemented by Rush University Medical Center and Practice Point Communications. Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statements
Rush University Medical Center designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Rush University Medical Center designates this enduring material for a maximum of 1.50 continuing nursing contact hour(s).
Rush University Medical Center designates this knowledge-based activity for a maximum of 1.50 contact hour(s) for pharmacists.
Disclosure Statements/FDA statement
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.
The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role. .
DISCLOSURES
The speakers and planning committee members listed below have no relevant financial relationships with ineligible companies.
RUMC: Jennifer Comerford, MA, CHCP; Arzo Hamidi, PharmD, BCCCP; Kathryn McAndrews, MSN, APRN; Cecilia Merino
PPC: Bronwyn Boyes, PharmD; Colleen Goodchild
Individuals in control of content for this activity have the following relevant financial relationships to disclose and all financial relationships have been mitigated.
FACULTY DISCLOSURES
Ayodeji Adegunsoye, MD, MSc, PhD, FCCP
Consultant: Abbvie, Baxter, Trainomix, Gossamer BIo, Inogen, InsMed, Medscape, PatientMpower, Pure Tech, Roche, Boehringer Ingelheim
Member, Speakers Bureau: Boehringer Ingelheim
Kevin Flaherty, MD
Consultant: AbbVie, Daewoong Pharmaceuticals, Mannkind, Orion Pharma, PureTech, Tempus Inc., United Therapeutics, Vicore
Steven Nathan, MD, FCCP
Research Grant/Investigator: United Therapeutics
Advisory Committee/Board: Avalyn Pharma, Boehringer-Ingelheim, PureTech, Trevi Therapeutics, United Therapeutics
Stockholder: Gossamer Bio
Speaker Bureau/Faculty/Peer Review: Boehringer-Ingelheim, Merck, United Therapeutics
Consultant: Avalyn Pharma, Boehringer-Ingelheim, PureTech, Trevi Therapeutics
Honoraria: Boehringer-Ingelheim, United Therapeutics
DISCLAIMER
The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.
PRIVACY POLICY
The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ABS or ANCC.
Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and United Therapeutics, a public benefit company